Lets review 2022 - BioProcess Insider's Big M&A of the Year!

As the year draws to a close, BioProcess Insider brings you our Christmas quiz special where we test your 2022 M&A knowledge.

Millie Nelson, Editor

December 21, 2022

1 Min Read
Lets review 2022 - BioProcess Insider's Big M&A of the Year!
DepositPhotos/NiroDesign

As the year draws to a close, BioProcess Insider brings you our Christmas quiz special where we test your 2022 M&A knowledge.

2022 has been a year full of M&A activity, some with big price tags and others that have seen companies move into different modalities and service offerings. BioProcess Insider wanted to bring our readers some festive fun ahead of Christmas and the New Year.

Happy Christmas from Bioprocess Insider and here’s to another year full M&A activity!

Loading…

About the Author(s)

Millie Nelson

Millie Nelson

Editor, BioProcess Insider

Journalist covering global biopharmaceutical manufacturing and processing news and host of the Voices of Biotech podcast.

I am currently living and working in London but I grew up in Lincolnshire (UK) and studied in Newcastle (UK).

Got a story? Feel free to email me at [email protected]

See more from Millie Nelson

You May Also Like

Webinars

ask the expert webcast
ATE Webcasts
More Product Faster: Maximize mAbs, Cell Therapy, and Gene Therapy Production with Upstream Process IntensificationMore Product Faster: Maximize mAbs, Cell Therapy, and Gene Therapy Production with Upstream Process Intensification
scientist at OPUS 80R
Sponsored Content
Reduce Risk and Enable Continuous Manufacturing Using Pre-Packed Columns for Multicolumn ChromatographyReduce Risk and Enable Continuous Manufacturing Using Pre-Packed Columns for Multicolumn Chromatography
Resilience logo
Sponsored Content
Built to Serve Innovation: A Briefing on Commercial Readiness at ResilienceBuilt to Serve Innovation: A Briefing on Commercial Readiness at Resilience
Latest Content
Sep 23 - Sep 26, 2024
Learn from the brightest minds in bioprocessing! The BPI US 2024 scientific agenda includes 200+ of the industry's top scientists to present the latest updates on how to improve efficiencies across all phases of biopharmaceutical development and production.
Learn More